Temozolomide as Maintenance Therapy in Small Cell Lung Cancer

Status Active, not recruiting

Clinical Trial Summary

Temozolomide, a nonclassic oral alkylating agent, may delay progression in sequence with chemotherapy. This phase II trial was designed to evaluate the role of Temozolomide following 4 or 6 cycles of first-line treatment in patients with newly diagnosed SCLC.

Clinical Trial Description

Subjects will receive standard of care treatment for SCLC with added treatment of maintenance temozolomide. Efficacy and safety of temozolomide and one year survival and time to progression of patients will be recorded. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01900951
Study type	Interventional
Source	Chinese PLA General Hospital
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	January 2013
Completion date	June 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01860898` - A Phase I Study of iPS Cell Generation From Patients With COPD	N/A
Completed	`NCT00046787` - Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer	Phase 2
Recruiting	`NCT03212404` - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers	Phase 1
Recruiting	`NCT03554473` - M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers	Phase 1/Phase 2
Terminated	`NCT00094978` - Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum	Phase 1
Recruiting	`NCT04162041` - Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer	Phase 2
Completed	`NCT03092739` - A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
Completed	`NCT00305942` - Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer	Phase 2
Terminated	`NCT00324558` - Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)	Phase 2
Completed	`NCT00359359` - A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer	Phase 1/Phase 2
Completed	`NCT00191750` - A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned	Phase 2
Recruiting	`NCT05461430` - Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Recruiting	`NCT02366741` - Neurocognitive Function After Prophylactic Cranial Irradiation & Hippocampal Sparing in LD SCLC Patients - a Pilot Study	N/A
Completed	`NCT00826644` - Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient	Phase 3
Completed	`NCT00284154` - Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer	Phase 2
Recruiting	`NCT00100256` - Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy	Phase 1/Phase 2
Completed	`NCT00126828` - Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer	Phase 1/Phase 2
Terminated	`NCT02034123` - Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma	Phase 1
Recruiting	`NCT05500391` - Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring	Phase 2
Recruiting	`NCT02688036` - Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC	Phase 3